Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
LENZ Therapeutics’ Merger with Graphite Bio
MapLight Therapeutics’ $225 Million Series C Funding Round
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction. MapLight Therapeutics announced a $225 million Series C financing co-led by Novo Holdings, 5AM Ventures, Cowen...
Iambic Therapeutics’ $100 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction. Iambic Therapeutics announced the closing of an oversubscribed $100 million Series B financing. The round was co-led by...
SpyGlass Pharma’s $90 Million Series C Financing
Wilson Sonsini Goodrich & Rosati represented SpyGlass in the transaction. SpyGlass Pharma announced the closing of $90 million in Series C financing. The financing, which was led...
LENZ Therapeutics’ $83.5 Million Series B Financing
Wilson Sonsini Goodrich & Rosati represented LENZ in the transaction. Biopharmaceutical company LENZ Therapeutics announced that it raised $83.5 million in an oversubscribed Series B financing....
LinusBio’s $16 Million Financing to Help Diagnose Autism
Wilson Sonsini advised LinusBio on the deal. Linus Biotechnology received $16 million in venture capital financing for its R&D efforts to establish a method for predicting...
Metagenomi’s $100 Million Series B Extension Financing
Wilson Sonsini Goodrich & Rosati advised Novo Holdings and Metagenomi on the deal. Fenwick represented Metagenomi. Gene editing company Metagenomi announced a $100 million Series B...
Escient Pharmaceuticals’ $120 Million Series C Financing
Wilson Sonsini Goodrich & Rosati advised NEA and Abingworth on the transaction. Escient Pharmaceuticals announced that it had raised $120 million through a Series C Financing...
Rezo Therapeutics’ $78 Million Series A Financing
Wilson Sonsini represented lead investors SR One and Norwest in the transaction. Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision...
Inversago Pharma’s $70 Million Series C Financing
White & Case and Osler, Hoskin & Harcourt LLP advised Inversago Pharma Inc. on the deal, while Wilson Sonsini advised NEA. Inversago Pharma Inc., a clinical-stage...
BIOMILQ, Inc.’s $21 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the deal. North Carolina-based mammary biotechnology company BIOMILQ, Inc., announced the successful close of $21 million in...
ARS Pharmaceuticals’ $55 Million Series D Financing
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better...